Status™ COVID-19/Flu A&B, rapid antigen immunoassay
Principle: For the direct detection of SARS-CoV-2, Influenza Type A and Type B
Approvals: FDA EUA
Suitability: Rapid Detection
Capital equipment required: NO
A rapid immunoassay for the simultaneous direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A and Type B antigen from nasopharyngeal swab specimens. Flocked nasopharyngeal swab for superior specimen collection and patient comfort.
Sensitivity and Specificity
- SARS-CoV-2 - Sensitivity 93.9%, Specificity 100%
- Flu A - Sensitivity 91.4%, Specificity 95.7%
- Flu B - Sensitivity 87.6%, Specificity 95.9%
Features and benefits:
- Fast results:
Visual read-out in 15 minutes, and no equipment needed!
- FDA EUA
Approved under FDA Emergency Use Authorization (EUA)
- Swab included:
Kit includes extraction buffer vials and flocked nasopharyngeal swabs for superior specimen collection and patient comfort.
Click here for more information